CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤 CAR-T 细胞与双特异性抗体治疗期间感染预防的建议
英文原题：Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
查看英文原题
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）细胞和双特异性抗体疗法在既往接受过大量治疗的多发性骨髓瘤（MM）患者中显示出前所未有的疗效。然而，其使用与严重感染的显著风险相关，这可归因于多种因素，如低丙种球蛋白血症、中性粒细胞减少、淋巴细胞减少、T细胞耗竭、细胞因子释放综合征和免疫效应细胞相关神经毒性综合征。由于这些疗法最近已获得监管机构批准，在前瞻性临床试验获得可靠数据之前，建立感染监测和预防的实用指南至关重要。为解决这一问题，来自通过创新试验克服多发性骨髓瘤学术联盟（COMMIT）的一组经验丰富的研究者制定了共识建议，以减轻MM患者中与CAR-T 细胞和双特异性抗体疗法相关的感染。
展开英文摘要原文
Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM).
However, their use is associated with a significant risk of severe infections, which can be attributed to various factors such as hypogammaglobulinemia, neutropenia, lymphopenia, T-cell exhaustion, cytokine-release syndrome and immune-effector cell-associated neurotoxicity syndrome. As these therapies have been recently approved by regulatory agencies, it is crucial to establish practical guidelines for infection monitoring and prevention until robust data from prospective clinical trials become available.
To address this issue, a panel of experienced investigators from the Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT) developed consensus recommendations for mitigating infections associated with CAR T-cell and bispecific antibody therapies in MM patients.
论文信息
- 作者
- Mohan M、Chakraborty R、Bal S、Nellore A、Baljevic M、D'Souza A、Pappas PG、Berdeja JG
- 第一作者单位
- Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.United States
- 通讯作者单位
- Division of Hematology and Medical Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.United Kingdom
- 文献类型
- 病例报告 · 美国 NIH 资助研究
- 期刊
- British journal of haematology2023 Dec
- 原文标识
- PubMed 37287117 · DOI 10.1111/bjh.18909
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →